David Hyman

Dr. David Hyman is a clinical oncologist and drug developer who led the clinical development of larotrectinib, the first tumor-agnostic FDA-approved cancer therapy targeting NTRK fusions. He pioneered basket trial design principles for histology-independent oncology drug development and has contributed to regulatory frameworks for tumor-agnostic approvals. His work fundamentally changed how oncology drugs can be developed and approved beyond single cancer types.